231 related articles for article (PubMed ID: 31602715)
21. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.
Krüger K; Krauth C; Rossol S; Mauss S; Boeker KHW; Müller T; Klinker H; Pathil A; Heyne R; Stahmeyer JT;
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):230-240. PubMed ID: 30325794
[TBL] [Abstract][Full Text] [Related]
22. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.
Kattakuzhy S; Wilson E; Sidharthan S; Sims Z; McLaughlin M; Price A; Silk R; Gross C; Akoth E; McManus M; Emmanuel B; Shrivastava S; Tang L; Nelson A; Teferi G; Chavez J; Lam B; Mo H; Osinusi A; Polis MA; Masur H; Kohli A; Kottilil S
Clin Infect Dis; 2016 Feb; 62(4):440-447. PubMed ID: 26503379
[TBL] [Abstract][Full Text] [Related]
23. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
[TBL] [Abstract][Full Text] [Related]
24. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
[TBL] [Abstract][Full Text] [Related]
25. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H
J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470
[TBL] [Abstract][Full Text] [Related]
26. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.
Zarębska-Michaluk D; Brzdęk M; Jaroszewicz J; Tudrujek-Zdunek M; Lorenc B; Klapaczyński J; Mazur W; Kazek A; Sitko M; Berak H; Janocha-Litwin J; Dybowska D; Supronowicz Ł; Krygier R; Citko J; Piekarska A; Flisiak R
World J Gastroenterol; 2022 Dec; 28(45):6380-6396. PubMed ID: 36533109
[TBL] [Abstract][Full Text] [Related]
27. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
28. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
[TBL] [Abstract][Full Text] [Related]
29. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Takaguchi K; Toyoda H; Tsutsui A; Suzuki Y; Nakamuta M; Imamura M; Senoh T; Nagano T; Tada T; Tachi Y; Hiraoka A; Michitaka K; Shibata H; Joko K; Okubo H; Tsuji K; Takaki S; Watanabe T; Ogawa C; Chayama K; Kumada T; Kudo M; Kumada H
J Gastroenterol; 2019 Aug; 54(8):742-751. PubMed ID: 30848363
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR
J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232
[TBL] [Abstract][Full Text] [Related]
31. Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
van Tilborg M; Lieveld FI; Smolders EJ; van Erpecum KJ; de Kanter CTMM; Maan R; van der Valk M; Arends JE; Dofferhoff ASM; Blokzijl H; Bijmolen M; Drenth JPH; de Knegt RJ; Burger DM;
Aliment Pharmacol Ther; 2017 Nov; 46(9):864-872. PubMed ID: 28881031
[TBL] [Abstract][Full Text] [Related]
32. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
[TBL] [Abstract][Full Text] [Related]
33. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
Pabjan P; Brzdęk M; Chrapek M; Dziedzic K; Dobrowolska K; Paluch K; Garbat A; Błoniarczyk P; Reczko K; Stępień P; Zarębska-Michaluk D
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062302
[TBL] [Abstract][Full Text] [Related]
34. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
Backus LI; Belperio PS; Shahoumian TA; Mole LA
Hepatology; 2018 Sep; 68(3):827-838. PubMed ID: 29377196
[TBL] [Abstract][Full Text] [Related]
35. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
36. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
[TBL] [Abstract][Full Text] [Related]
37. Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.
Dybowska D; Zarębska-Michaluk D; Rzymski P; Berak H; Lorenc B; Sitko M; Dybowski M; Mazur W; Tudrujek-Zdunek M; Janocha-Litwin J; Janczewska E; Klapaczyński J; Parfieniuk-Kowerda A; Piekarska A; Sobala-Szczygieł B; Dobrowolska K; Pawłowska M; Flisiak R
World J Gastroenterol; 2023 Jul; 29(25):4085-4098. PubMed ID: 37476581
[TBL] [Abstract][Full Text] [Related]
38. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
Morio K; Imamura M; Kawakami Y; Nakamura Y; Hatooka M; Morio R; Fujino H; Nakahara T; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Katamura Y; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
J Med Virol; 2018 Dec; 90(12):1834-1840. PubMed ID: 30016555
[TBL] [Abstract][Full Text] [Related]
39. Sustained virologic response with 6 weeks or less of direct-acting antiviral therapy for chronic hepatitis C: Experience at a veterans affairs healthcare system.
Joshi P; Atherton A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2173-2178. PubMed ID: 31062412
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study.
Yek C; de la Flor C; Marshall J; Zoellner C; Thompson G; Quirk L; Mayorga C; Turner BJ; Singal AG; Jain MK
BMC Med; 2017 Nov; 15(1):204. PubMed ID: 29151365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
